What is the recommended upper limit for mean arterial pressure (MAP) in a patient with septic shock who is receiving vasopressor therapy?

Upper Limit MAP Goal in Septic Shock

The recommended upper limit for mean arterial pressure (MAP) in septic shock is 85 mmHg, with an initial target of 65 mmHg for most patients. 1

Initial MAP Target

• Target a MAP of 65 mmHg initially during vasopressor therapy (strong recommendation, moderate quality evidence). 1
• This 65 mmHg threshold represents the lower limit of cerebral and renal autoregulation in most patients, below which organ perfusion becomes pressure-dependent. 1

Upper Limit Considerations

Standard Patients (No Chronic Hypertension)

• Do not exceed MAP targets of 70-85 mmHg in patients without chronic hypertension, as higher targets provide no mortality benefit and may increase harm. 2
• The landmark SEPSISPAM trial demonstrated no mortality difference at 28 days (36.6% vs 34.0%) or 90 days (43.8% vs 42.3%) when targeting MAP 80-85 mmHg versus 65-70 mmHg. 2
• Higher MAP targets (80-85 mmHg) increased the incidence of atrial fibrillation without improving outcomes. 2

Patients with Chronic Hypertension

• Consider targeting MAP 80-85 mmHg in patients with documented chronic hypertension to reduce acute kidney injury and need for renal replacement therapy. 2, 3
• In the SEPSISPAM trial subgroup analysis, chronically hypertensive patients in the high-target group (80-85 mmHg) required less renal replacement therapy, though this did not translate to mortality benefit. 2
• This represents the practical upper limit for MAP targets in septic shock. 3

Critical Timing Considerations

• Avoid escalating to higher MAP targets if patients have been on vasopressors for more than 6 hours, as this is associated with increased mortality (OR 3.00,95% CI 1.33-6.74). 4
• A pooled analysis of 894 patients demonstrated that targeting higher blood pressure increased mortality risk specifically in patients who had prolonged vasopressor exposure before randomization. 4

Physiologic Rationale Against Excessive Targets

• Increasing MAP from 65 to 85 mmHg with norepinephrine does not improve metabolic variables or renal function in patients without chronic hypertension. 5
• Above the autoregulation threshold of 60-65 mmHg, excessive vasopressor-induced vasoconstriction can be deleterious to microcirculatory perfusion. 1
• Higher MAP targets requiring high norepinephrine doses or failing to resolve mottled skin at 24 hours are associated with increased mortality. 6

Practical Algorithm

1. Start with MAP target of 65 mmHg for all patients 1

2. Assess for chronic hypertension:

   • If present: Consider increasing target to 75-85 mmHg (maximum 85 mmHg) 2, 3
   • If absent: Maintain 65-70 mmHg target 2

3. Monitor duration of vasopressor therapy:

   • If >6 hours on vasopressors: Do not escalate MAP targets 4
   • If requiring high norepinephrine doses or persistent mottling: Do not escalate MAP targets 6

4. Never exceed 85 mmHg as upper limit regardless of patient characteristics 2

Common Pitfalls

• Avoid using MAP alone as a surrogate for organ perfusion, especially when intracranial, intra-abdominal, or tissue pressures may be elevated. 7
• Do not assume all chronically hypertensive patients need higher targets—the benefit is primarily in reducing acute kidney injury, not mortality. 2
• Recognize that individual organ perfusion pressures vary: brain requires 50-70 mmHg, kidneys 65 mmHg, hepato-splanchnic flow >50 mmHg. 7
• Titrate based on measures of organ function and tissue perfusion (lactate clearance, urine output, mental status, skin mottling) rather than MAP alone. 7, 6